TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including GLP-1 therapies, to older adults. It calls for assessing function, nutrition and cognition before treatment and pairing medication with measures such as resistance exercise and adequate protein intake.
The American Geriatrics Society (AGS) has published a case-based framework to help clinicians prescribe obesity medications safely and in line with older patients’ needs. The paper applies the society’s Geriatrics 5Ms approach to incretin therapies, including GLP-1 medications, and stresses evaluating physical function, nutrition and cognition before treatment.
The paper, titled “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing,” appeared in the Journal of the American Geriatrics Society. Developed by the AGS Healthy Aging Special Interest Group, it uses clinical cases to discuss how to assess the potential role of obesity medications in older adults rather than treating age as a stand-alone prescribing rule.
The 5Ms framework organizes decisions around Mind, Mobility, Medications, Multicomplexity and Matters Most—including cognition, physical function, other health conditions and the patient’s own priorities. The authors recommend pretreatment assessment of functional status, nutritional adequacy and cognitive impairment. They also identify age-related concerns including frailty, sarcopenia, loss of lean muscle, malnutrition and dehydration.
The paper says medication should be considered alongside supportive measures. Its authors recommend pairing treatment with resistance training and adequate dietary protein. Depending on a patient’s needs, care may involve a team that includes a registered dietitian, physical therapist, fitness trainer or behavioral health professional. The report describes possible benefits of these medicines for weight management, blood-sugar control and other health conditions, while noting that older adults have been underrepresented in clinical trials.
Balancing Weight Treatment With Function
The framework addresses a prescribing challenge: a medication’s potential benefits must be weighed against the health and functional needs of the individual older patient. Concerns such as muscle loss, frailty and inadequate nutrition make it relevant to assess more than weight or blood-sugar measures when discussing treatment.
Its emphasis on patient priorities also places the decision within a broader care plan. A clinician may need to consider mobility, other medications, cognitive status and practical access to nutrition or exercise support. The paper offers a way to structure those discussions; it does not, based on the report, establish that a particular medicine is appropriate for every older adult or provide new trial results showing outcomes from the framework.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Bowflex SelectTech 840 Adjustable Kettlebell
Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms
The AGS 5Ms are a geriatrics framework intended to bring together issues that can shape care for older adults: Mind, Mobility, Medications, Multicomplexity and Matters Most. The new paper applies those categories to incretin therapy, a group of treatments that includes GLP-1 medications and acts through gut-derived hormonal pathways.
The report says the drugs may offer benefits for weight management and glycemic control, but also points to a limitation in the evidence base: older adults are underrepresented in clinical trials. The framework therefore foregrounds individual assessment and monitoring considerations. The publication is by Elias M. Wisdom and co-authors in the Journal of the American Geriatrics Society (2026; DOI: 10.1111/jgs.70769).
“Safe prescribing requires pretreatment assessment of functional status, nutritional adequacy and cognitive impairment.”
— The AGS Healthy Aging Special Interest Group paper
Evidence Gaps and Individual Decisions
The available report does not provide clinical trial results testing the framework or quantify how often older adults experience the listed risks. It also does not specify which patients should receive a particular medication, how clinicians should adjust doses, or how treatment effects should be monitored over time.
Because older people are underrepresented in trials, the report does not resolve how well findings from broader study populations apply to different older adults, including those with frailty or multiple health conditions. The paper is guidance for clinical decision-making, not evidence that the framework itself improves health outcomes. Individual treatment decisions remain a matter for patients and qualified clinicians.
Using the Framework in Care
The publication provides clinicians with a structure for considering obesity medications through the 5Ms, including assessment before prescribing and attention to nutrition and physical function during care. The source report does not announce a rollout schedule, formal implementation program or planned follow-up study.
Further research would be needed to clarify outcomes for older adults, particularly those underrepresented in existing trials, and to evaluate how medication combined with exercise and nutritional support affects function and health. For now, the paper’s practical next step is individualized discussion among clinicians and patients, with additional professionals involved when a patient’s needs call for team-based care.
Key Questions
What did the American Geriatrics Society publish?
The AGS Healthy Aging Special Interest Group published a case-based framework for considering obesity medications in older adults in the Journal of the American Geriatrics Society.
Which medications does the framework discuss?
It addresses incretin therapies, including GLP-1 medications, in the broader category of obesity medications. The report does not recommend one specific drug for all older adults.
What should clinicians assess before prescribing?
The paper recommends assessing functional status, nutritional adequacy and cognitive impairment, while considering issues such as frailty, sarcopenia, lean muscle loss, malnutrition and dehydration.
What should accompany medication treatment?
The authors recommend resistance training and adequate dietary protein. Depending on the patient, care may also involve a dietitian, physical therapist, fitness trainer or behavioral health professional.
Does the framework show that these drugs are safe for every older adult?
No. The paper is a clinical decision framework, not evidence that a medication is suitable for every older adult. The report notes that older adults are underrepresented in clinical trials, and treatment decisions require individual assessment by a qualified clinician.
Source: medicalxpress.com
